EMA Withdrawn: Docetaxel Zentiva (previously Docetaxel Winthrop) (docetaxel) — Zentiva k.s.

View source ↗

Summary

The EMA has withdrawn Docetaxel Zentiva (docetaxel) from the market. The therapeutic areas formerly associated include head and neck neoplasms, non-small cell l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma
• Breast Neoplasms
• Head and Neck Neoplasms
• Non-small Cell Lung Carcinoma
• Prostatic Neoplasms
• Stomach Neoplasms

Drugs mentioned

• Docetaxel Zentiva (docetaxel)

Snippet

Status: Withdrawn. Therapeutic area: Head and Neck Neoplasms;Carcinoma, Non-Small-Cell Lung;Adenocarcinoma;Prostatic Neoplasms;Stomach Neoplasms;Breast Neoplasms. MAH: Zentiva k.s.. Decision date: 25/04/2022